DOCSLIB.ORG

Christopher G. CHUTE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Christopher G. CHUTE Members of the Revision Steering Group for the revision of the International Classification of Diseases Christopher G. CHUTE Chair: Revision Steering Group Dr. Chute received his undergraduate and medical training at Brown University, internal medicine residency at Dartmouth, and doctoral training in Epidemiology at Harvard. He is Board Certified in Internal Medicine, and a Fellow of the American College of Physicians, the American College of Epidemiology, and the American College of Medical Informatics. He became founding Chair of Biomedical Informatics at Mayo in 1988, stepping down after 20 years in that role. He is now Professor of Medical Informatics, and is PI on a large portfolio of research including the HHS/Office of the National Coordinator (ONC) SHARP (Strategic Health IT Advanced Research Projects) on Secondary EHR Data Use, the ONC Beacon Community (Co-PI), the LexGrid projects, Mayo’s CTSA Informatics, Mayo’s Cancer Center Informatics including caBIG, and several NIH grants including one of the eMERGE centers from NGHRI, which focus upon genome wide association studies against shared phenotypes derived from electronic medical records. Dr. Chute serves as Vice Chair of the Mayo Clinic Data Governance for Health Information Technology Standards, and on Mayo’s enterprise IT Oversight Committee. He is presently Chair, ISO Health Informatics Technical Committee (ISO TC215) and Chairs the World Health Organization (WHO) ICD-11 Revision. He also serves on strategic advisory panels to NCRR and NHGRI within NIH, and the Health Information Technology Standards Committee for the Office of the National Coordinator in the US DHHS. Recently held positions include Chair of the Biomedical Computing and Health Informatics study section at NIH, Chair of the Board of the HL7/FDA/NCI/CDISC BRIDG project, on the Board of the Clinical Data Interchange Standards Consortium (CDISC), ANSI Health Information Standards Technology Panel (HITSP) Board member, Chair of the US delegation to ISO TC215 for Health Informatics, Convener of Healthcare Concept Representation WG3 within the (TC215), Co-chair of the HL7 Vocabulary Committee, Chair of the International Medical Informatics Association (IMIA) WG6 on Medical Concept Representation, American Medical Informatics Association (AMIA) Board member, and multiple other NIH biomedical informatics study sections as chair or member. Contact: Mayo Clinic College of Medicine 710 9th Ave SW Rochester MN 55902, USA [email protected] Office: +1 (507) 284-5506 Fax: +1 (507) 284-0360 Members of the Revision Steering Group for the revision of the International Classification of Diseases Robert JG CHALMERS Chair: Dermatology Topic Advisory Group Dr Chalmers has been a consultant dermatologist in Manchester since 1983. He has major interests in the systemic treatment of psoriasis and in evidence-based dermatology. He has been interested in terminology for skin disease since the 1980s. He was closely involved in the development of the British Association of Dermatologists’ Index of Dermatological Diagnoses ( BAD Index ) which was developed in response to dissatisfaction with ICD for the codification of skin disease and was first published in 1994. Some 80 British dermatologists have contributed to its development and its subsequent revisions. He was also a member of the Dermatology Specialty Working Group which submitted terms to the UK National Health Service’s project to develop a generic healthcare terminology, Clinical Terms, in the mid-1990s. Clinical Terms was amalgamated in 1999 with the American generic healthcare terminology, SNOMED RT as SNOMED CT . The majority of terms in the BAD Index were submitted to Clinical Terms and thus appear in SNOMED CT . He has had a close interest in the further development of SNOMED CT . He contributed to the SNOMED CT multiprofessional quality assessment (MPQA) exercise to which he and colleagues contributed in 2002 soon after SNOMED CT was first published. As a result of these efforts the BAD was invited to work with the International SNOMED organisation and a further 2,000 dermatological terms which had not been included were added to SNOMED CT in 2004. He has also worked closely with Professors Mark Pittelkow and Peter Elkin of the Mayo Clinic, Rochester, Minnesota in evaluation of the dermatology content of SNOMED CT vis-à-vis the BAD Index , and more recently, of the Dermatology Lexicon . In 2001 he was invited on to the Advisory Board of the Dermatology Lexicon Project by Professor Lowell Goldsmith and colleagues and visited them in Rochester, New York, in December of that year to advise on the Project. He has been keen to see the development of a standardised reference terminology for dermatology and convened a meeting of interested parties at the World Congress in Buenos Aires in October 2007 to discuss the feasibility of this. Contact: Robert Chalmers Department of Dermatology Dermatology Centre Manchester Royal Infirmary University of Manchester School of Medicine Oxford Road Stott Lane Manchester M13 9WL UK Eccles Manchester M6 8HD UK tel +44 (0) 161 276 4173 tel +44 (0) 161 206 1016 fax +44 (0) 161 276 8881 fax +44 (0) 161 206 1018 [email protected] Members of the Revision Steering Group for the revision of the International Classification of Diseases Michael WEICHENTHAL Co-Chair: Dermatology Topic Advisory Group Dr Weichenthal is a dermatologist based at the University of Kiel in Germany. He has research interests in the epidemiology and genetics of psoriasis. Further interests are in malignant melanoma and other skin malignancies as well as photobiology. Dr. Weichenthal has been involved in coding and classification of dermatological diseases since the 1990s. Since the retirement of Dr Tilo Henseler in 2000, Dr Weichenthal has led the Diagnostic Coding Working Group of the Deutsche Dermatologische Gesellschaft. This group has overseen the development and modification of an extended six-character German language clinical modification of the dermatology content of ICD10, the Dermatologischer Diagnosenkatalog mit ICD-10 Schlüssel (2000). It is in routine use by German dermatologists to enable them to make official returns to government and health insurance organisations. An English translation of the DDK was adopted by the ILDS as the preferred clinical modification of ICD10 and is available from the ILDS website. Dr. Weichenthal holds a degree in Medical Informatics and is responsible for the clinical skin cancer registry, being part of the Kiel based Comprehensive Cancer Centre North. Here he is engaged in implementing recent classification models for melanoma, cutaneous lymphomas and other skin malignancies. Contact: Dr Michael Weichenthal Klinik für Dermatologie, Venerologie und Allergologie Universitätsklinikum Schleswig-Holstein, Campus Kiel Schittenhelmstr. 7 24105 Kiel, Germany Tel.: 0431-597 1539 Fax: 0431-597 1606 [email protected] Members of the Revision Steering Group for the revision of the International Classification of Diseases James E. HARRISON Chair: External Cases and Injuries Topic Advisory Group Dr James Harrison is an injury epidemiologist who directs the Research Centre for Injury Studies at Flinders University, in South Australia. He is an Associate Professor in the School of Medicine at the university. The Research Centre operates the National Injury Surveillance Unit (NISU) of the Australian Institute of Health and Welfare, which he also directs. NISU is Australia’s national centre for injury surveillance. Its many publications are accessible on-line. Dr Harrison and the NISU team make extensive use of mortality data and hospital data classified according to the International Classification of Diseases (ICD). During the past decade, they have worked closely with Australia’s National Centre for Classification in Health concerning the injury and external causes chapters of the Australian clinical versions of ICD-9 and ICD-10, providing advice and making submissions concerning the content of revisions. Dr Harrison is currently a chief investigator in a project to evaluate the quality of ICD external cause coding of hospitalized injury cases in Australia. Dr Harrison has been actively involved with the development of the International Classification of External Causes of Injury (ICECI) since its inception, and is a member of the ICECI Coordination and Development Group. He is also a longstanding active participant in the International Collaborative Effort on Injury Statistics, convened by the US National Center for Health Statistics. Dr Harrison holds a degree in medicine from Melbourne University, a Master of Public Health degree from the University of Sydney, and is a Fellow of the Australasian Faculty of Public Health Medicine. His main areas of research interest are injury prevention and control, and methods and infrastructure for public health surveillance and evaluation, including classifications. Contact: Research Centre for Injury Studies Flinders University – School of Medicine National Injury Surveillance Unit AIHW, Sturt Road, Bedford Park, Adelaide, Australia [email protected] Members of the Revision Steering Group for the revision of the International Classification of Diseases Kentaro SUGANO Chair: Internal Medicine Topic Advisory Group Dr Kentaro Sugano received his doctorate and degree in medicine at the University of Tokyo. Further education at the Tokyo University Hospital led to the PhD. Dr Sugano did research at the University of California, and at the University of Michigan.
Load more

Recommended publications
  • Old Road Campus
    Old Road Campus 4a, 4b, 4c, U5 n o t Oxford City Centre g OLD ROAD n i d 4a, 4b, 4c, U5 a e H K O L L A D R O W AD E M I L 4,4a,4b,4c, U1X,U5 A41 42 4,4a,4b,4c,U5 Rin D 4 g R oad 6 7 1 13 3 11 C H U R C H I L L 900 D 2 R I 700, 900 V E E O x f o 5 A C rd 12 C i ty 10 C e n t re B 8 CAR PARK C 9 h u r c R F h i O l l O S H E o V s N E p L i T t DRI a VE ENTRANCE ROOSEVELT DRIVE l 900, ST2 Index 1 The Triangle Nursery 9 Old Road Campus Estates Annexe 13 Boundary Brook House Interserve Joint Research Office Kennedy Institute 2 - Research Services, Medical Sciences Division Old Road Campus Research Building 10 - Clinical Trials and Research Governance 3 New Richards Building Department of Oncology - Human Tissue Governance CRUK/MRC Oxford Institute for Radiation Oncology - Medical Sciences Division Business Development 4 NDM Research Building Institute of Biomedical Engineering Nuffield Department of Primary Care Health Sciences Target Discovery Institute Jenner Institute Medical Sciences Divisional Safety Officers Centre for Tropical Medicine and Global Health Bodleian Knowledge Centre (Library Services) Medical Sciences Division IT Services 5 Wellcome Centre for Human Genetics (WHG) Ludwig Institute for Cancer Research Structural Genomics Consortium 6 Henry Wellcome Building for Molecular Physiology Nuffield Department of Surgical Sciences Loading Bays and Delivery Offices of the Nuffield Professor of Medicine ENTRANCE VIA BUILDING 5 11 Big Data Institute A Wellcome Trust Centre for Human Genetics 7 Henry Wellcome Building for Particle Imaging
    [Show full text]
  • Downloaded From
    A Thesis Submitted for the Degree of PhD at the University of Warwick Permanent WRAP URL: http://wrap.warwick.ac.uk/149337 Copyright and reuse: This thesis is made available online and is protected by original copyright. Please scroll down to view the document itself. Please refer to the repository record for this item for information to help you to cite it. Our policy information is available from the repository home page. For more information, please contact the WRAP Team at: [email protected] warwick.ac.uk/lib-publications A Randomized Trial of Neprilysin Inhibition with Sacubitril/valsartan vs Irbesartan in Chronic Kidney Disease by Dr Parminder Kaur Judge Thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy (PhD) in Medicine University of Warwick & Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford Submitted June 2020 1 Contents Section Page List of Tables 7 List of Figures 9 Acknowledgements 10 Declarations 12 Inclusion of Published Work 13 Abstract 14 Chapters 1 List of abbreviations 15 2 Introduction 19 3 Natriuretic peptide system and neprilysin 35 2 4 Angiotensin receptor-neprilysin inhibitor (ARNI) 46 Effects on renal function 50 Effects on albuminuria 53 5 Methods 65 Trial organisation 70 Staff training 70 Data management 70 Trial treatments 70 Consent 72 Biological samples 73 Randomized treatment and blinding 76 Blood and urine samples 76 3 Adverse events and compliance with trial treatment 77 Physical measurements
    [Show full text]
  • 1 RECOVERY Central Coordinating Office Nuffield Department Of
    RECOVERY Central Coordinating Office Nuffield Department of Population Health Richard Doll Building Old Road Campus Roosevelt Drive Oxford OX3 7LF 24th May 2020 To all RECOVERY Principal Investigators Recruitment to the RECOVERY trial (including the Hydroxychloroquine arm) REMAINS OPEN On Friday 22nd May we received a letter from the MHRA in which they notified us of their concerns relating to the use of hydroxychloroquine as a treatment for patients with COVID-19 in the light of the recent publication by Mehra et al in The Lancet on 22 May 2020. We have held two videoconferences with the MHRA and provided a detailed response which is summarised below. This morning we have received written confirmation from the MHRA that, “it is acceptable to allow continued randomisation into the hydroxychloroquine arm of the trial.” Further details are provided below: • There have been two recent observational analyses of the use of hydroxychloroquine (HCQ) for treatment of COVID-19. One reported no significant effect on the outcome of intubation or death (Geleris et al, New Engl J Med 7 May 2020), while the other reported a hazard ratio of 1.33 for all-cause mortality (Mehra et al, Lancet 22 May 2020). The authors of both papers conclude that their findings should be interpreted with caution, are not definitive, and that randomised controlled trials are required to reach any conclusion about the benefit or harm of HCQ for COVID-19. • The RECOVERY trial is currently the largest randomised controlled trial of HCQ for COVID-19 but is not yet sufficiently large to detect (or rule out) moderate yet important treatment effects.
    [Show full text]
  • Nuffield Department of Population Health
    Nuffield Department of Population Health Richard Doll Building, Old Road Campus, Headington, Oxford OX3 7LF Tel: +44 (0)1865 743743, Fax: +44 (0)1865 743985, email: [email protected] _______________________________________________________________________________________________ 14 April 2014 Dr Fiona Godlee Editor, BMJ BMJ Publishing Group Tavistock Square London WC1H 9JR Dear Fiona NOT FOR PUBLICATION Thank you for responding so rapidly to my letter of 31 March, but unfortunately the key points that I raised have not been addressed properly either by the letters from Abramson et al and Malhotra or by your response of 1 April. I can assure you that this issue is not at all personal. As indicated previously, it seems highly likely that the misleading claims that have been reported by the BMJ about side- effect rates with statins will lead to large numbers of unnecessary heart attacks, strokes and premature deaths because patients at elevated risk will be dissuaded from taking statins. My concern is with the BMJ’s failure to correct promptly and prominently such a serious mistake when it has major public health implications. As I explained to you when we met, the evidence cited by Abramson et al and Malhotra does not support their claims that statins cause side-effects in 18-20% of patients. For the sake of clarity, a “statin-related adverse event” (which is what was studied in the paper by Zhang et al that is being cited) is not necessarily caused by, or a side-effect of, a statin. Consequently, it is a serious misrepresentation of the evidence for Abramson et al and Malhotra to state that it is.
    [Show full text]
  • Job Description and Selection Criteria Introduction
    George Institute for Global Health at University of Oxford University of Oxford New Richards Building Old Road Campus, Roosevelt Drive Oxford OX3 7LF United Kingdom T: +44 1865 617 203 F: +44 1865 617 202 [email protected] www.georgecentre.ox.ac.uk Job description and selection criteria Job title Executive Director, The George Institute for Global Health, China and James Martin Fellow, The George Institute for Global Health, University of Oxford Division Medical Sciences Department Nuffield Department of Population Health Location The George Institute at the University of Oxford, Richard Doll Building, Old Road Campus, Headington, Oxford (30%) and The George Institute at Peking University Health Science Center, Haidian District, Beijing (70%) Grade and salary Competitive Salary (RSIV grade) Hours Full time Contract type Fixed term, 5 Years Reporting to Principal Director, The George Institute for Global Health Vacancy reference Introduction The University of Oxford is a complex and stimulating organisation, which enjoys an international reputation as a world-class centre of excellence in research and teaching. It employs over 10,000 staff and has a student population of over 20,000. Most staff are directly appointed and managed by one of the University’s 130 departments or other units within a highly devolved operational structure - this includes 5,600 ‘academic- related’ staff (postgraduate research, computing, senior library, and administrative staff) and 2,700 ‘support’ staff (including clerical, library, technical, and manual staff). There are also over 1,600 academic staff (professors, readers, lecturers), whose appointments are in the main overseen by a combination of broader divisional and local faculty board/departmental structures.
    [Show full text]
  • Old Road Campus
    Old Road Campus 4a, 4b, 4c, U5 n Oxford City Centre OLD ROAD gto din 4a, 4b, 4c, U5 a He K O L LD A ROAD 4 W 4a E M 4b I 4c L U1X U5 A 414 2 Ri D 6 ng Ro □ 4 ad 4a 8 ■9 4b 1 4c U5 5 2 10 15 CHURCHILL DRIVE ■ 3 • BUILDING 13 WORKS 900 17 4 700, 900 E O x f or 7 A C d 16 C ity ■ Cent 14 BUILDING WORKS re • B 11 TEMPORARY CARPARK Churchill Hospital 12 [eJ R O O S E N V EL T DRIVE ENTRANCE ROOSEVELT DRIVE 900 Index 1 Nursery 11 Richard Doll Building 15 BDI (under construction) ■ Nuffi eld Department of Population Health ■ Kitchens (deliveries only) ■ Amenities (under construction) ■2 Cancer Epidemiology Unit ■16 3 Site Security Services Clinical Trial Service Unit 17 Mace National Perinatal Epidemiology Unit ■ ■ Kennedy Institute 4 Regius Professor Loading Bays and Delivery ■ New Richards Building 5 12 Old Road Campus Estates Annexe ■ Nuffi eld Department of Population Health ■ ~4'- □A Wellcome Trust Centre for Human Genetics NDM Research Building B Richard Doll Building 6 'j Interserve Ingenuity at work □ ■ Target Discovery Institute C Old Road Campus Research Building Centre for Tropical Medicine and Global Health □ 13 MSD IT Services D NDM Research Building 7 Henry Wellcome Building for Genomic Medicine ■ □ ■ 14 Old Road Campus Research Building E Kennedy Institute 8 Henry Wellcome Building for Molecular Physiology ■ Department of Oncology □ ■ Offi ces of the Nuffi eld Professor of Medicine CRUK/MRC Oxford Institute for Radiation Oncology ~ Cycle Racks ~ Motor Bike Parking ENTRANCE VIA BUILDING ■7 Institute of Biomedical Engineering [Ii!] Café 9 Henry Wellcome Building for Particle Imaging Jenner Institute ~ Entrances ■ ENTRANCE VIA BUILDING ■7 Bodleian Knowledge Centre (Library Services) Ludwig Institute for Cancer Research Quad Offices 10 Structural Genomics Consortium ENTRANCE VIA BUILDING 7 ■ ■ Nuffi eld Department of Surgical Sciences Parking Rules Private parking.
    [Show full text]
  • Health Services Research Unit
    Participant Information Sheet (version 26.6.2018) Health Services Research Unit Nuffield Department of Population Health Richard Doll Building, Old Road Campus, Headington, Oxford OX3 7LF Telephone 01865 289432 or email [email protected] Telephone 01865 289424 or email [email protected] Pretesting new items for the Parkinson’s Disease Questionnaire (PDQ) (ETHICS APPROVAL REFERENCE R58649/RE001) 1. What is the purpose of the study? The Parkinson’s Disease Questionnaire (PDQ) was developed in 1997 to measure the effects of Parkinson’s on every day life. Researchers in the Health Services Research Unit (HSRU) at the University of Oxford have recently conducted a series of interviews with people with Parkinson’s in order to explore whether additional questions for the PDQ are required in light of changes in the management of Parkinson’s over the last 20 years. Between 1 August and 30 October 2018 we will be conducting interviews with a small number of people with Parkinson’s to test a pool of newly generated PDQ questions. This is to ensure that the proposed questions are relevant, acceptable, unambiguous and usable. 2. Why have I been asked to take part in the study? You are being approached because you are a member of Parkinson’s UK and your local branch or the Research Support Network is helping to promote the project. We are looking for between 12 and 20 adults with Parkinson’s to take part. You must be over 18 years old, live in the UK, have access to the internet and use your computer or other electronic device to complete the proposed new questions online.
    [Show full text]
  • Parking Rules Loading Bays and Delivery
    Old Road Campus 4a, 4b, 4c, U5 n o Oxford City Centre OLD ROAD t ng 4a, 4b, 4c, U5 di ea H K O L LD A R 4 OA W D E 4a M 4b I L 4c U1X U5 A4 142 Rin E 6 g Ro 4 ad 4a 8 9 4b 1 4c U5 5 2 CHURCHILL DRIVE 3 D 900 4 700, 900 F O x for 7 A C d Cit y 12 C ent re B 10 11 Churchill Hospital R O O S E N V EL T D RIVE ENTRANCE ROOSEVELT DRIVE 900 Index 1 The Triangle 9 Henry Wellcome Building for Particle Imaging 12 Old Road Campus Research Building ENTRANCE VIA BUILDING 7 Department of Oncology, Cancer Research 2 Rosemary Rue Building UK/MRC Gray Institute for Radiation 10 Reception Richard Doll Building Oncology & Biology Nuffield Department of Population Health Nuffield Department of Population Health Institute of Biomedical Engineering Jenner Institute 3 Site Security Services Cancer Epidemiology Unit Clinical Trial Service Unit Bodleian Knowledge Centre (Library Services) 4 Kennedy Institute National Perinatal Epidemiology Unit Ludwig Institute for Cancer Research Structural Genomics Consortium 5 New Richards Building Regius Professor Nuffield Department of Population Health – NPEU 11 Old Road Campus Estates Annexe Childhood Cancer Research Group Loading Bays and Delivery 6 NDM Research Building A Wellcome Trust Centre for Human Genetics Target Discovery Institute and Tropical Medicine B Richard Doll Building 7 Henry Wellcome Building for Genomic Medicine C Old Road Campus Research Building 8 Henry Wellcome Building for Molecular Physiology D Offices of the Nuffield Professor of Medicine Rosemary Rue Restaurant ENTRANCE VIA BUILDING 7 NDM Research Building Kennedy Institute Parking Rules Cycle Path Private parking.
    [Show full text]
  • Aspirin in Patients Admitted to Hospital with COVID-19 (RECOVERY): a Randomised, Controlled, Open-Label, Platform Trial
    medRxiv preprint doi: https://doi.org/10.1101/2021.06.08.21258132; this version posted June 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Aspirin for COVID-19 1 2 3 Aspirin in patients admitted to hospital with 4 COVID-19 (RECOVERY): a randomised, controlled, 5 open-label, platform trial 6 7 Running title: Aspirin for COVID-19 8 9 RECOVERY Collaborative Group* 10 11 12 *The writing committee and trial steering committee are listed at the end of this 13 manuscript and a complete list of collaborators in the Randomised Evaluation of 14 COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix. 15 16 Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central 17 Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 18 7LF, United Kingdom. 19 Email: [email protected] 20 21 Word count: 22 Abstract – 301 words 23 Main text – 3085 words 24 References – 33 25 Tables & Figures – 2 + 3 26 27 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2021.06.08.21258132; this version posted June 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Active Monitoring for Atrial Fibrillation a Randomized Controlled Trial of Screening for Silent Atrial Fibrillation in H
    Date and version No: 2021-06-08 Version 2.0 ISRCTN 15544176 AMALFI: Active Monitoring for AtriaL Fibrillation A randomized controlled trial of screening for silent atrial fibrillation in high-risk individuals. Ethics Ref: 19/LO/0220 Date and Version No: 2021-06-08 V2.0 Chief Investigator: Professor Louise Bowman Investigators: Professor Barbara Casadei Dr Guilherme Pessoa-Amorim Dr Nicholas Jones Dr Christine A’Court Mr Richard Bulbulia Mrs Georgina Buck Sponsor: University of Oxford Funder: NIHR, Oxford Biomedical Research Centre (BRC) Chief Investigator Signature: AMALFI Central Coordinating Office, Clinical Trial Service Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK Tel: Freephone 0808 164 5080 or: +44 (0) 1865 743884 Email: [email protected], website: www.amalfitrial.org Chief Investigator: Professor Louise Bowman Short Title: AMALFI Ethics Ref: 19/LO/0220 Page 1 of 26 Date and version No: 2021-06-08 Version 2.0 ISRCTN 15544176 TABLE OF CONTENTS 1. SYNOPSIS ............................................................................................................................................... 4 2. ABBREVIATIONS ..................................................................................................................................... 5 3. BACKGROUND AND RATIONALE ............................................................................................................ 6 3.1 AF: A global health problem associated with substantial morbidity and mortality ...........................
    [Show full text]
  • Health Services Research Unit
    Participant information sheet v 15.5.2018 Health Services Research Unit Nuffield Department of Population Health Richard Doll Building, Old Road Campus, Headington, Oxford OX3 7LF Telephone 01865 289424 or email [email protected] Telephone 01865 289432 or email [email protected] Pretesting the PDQ-Carer in electronic format Ethics Approval Reference: RS56991/REE001 1. What is the purpose of this research? Researchers in the Health Services Research Unit (HSRU) at the University of Oxford have recently developed the Parkinson’s Disease Carer Questionnaire (PDQ-Carer) in order to measure the effects of being a carer for someone with Parkinson’s disease. The PDQ-Carer is being transferred to an electronic format so it can be used on personal computers, laptops, tablet computers and smart phones. We are conducting interviews with a small number of carers for people with Parkinson’s disease to assess its usability and acceptability, to ensure that it can be used successfully online. 2. Why have I been invited to take part? You are being approached because you are an informal carer for someone with Parkinson’s who is a member of Parkinson’s UK and your local branch or the Research Support Network is helping to promote the project. For this research what is meant by ‘informal carer’ is a family member or friend who provides help and support to a person with Parkinson’s disease but is not paid for it. We are looking for between six and ten informal carers to complete an online questionnaire and be interviewed about it.
    [Show full text]
  • Lectures and Seminars, Michaelmas Term 2015
    WEDNESDay 7 octobEr 2015 • SUPPLEMENt (1) to No 5107 • VoL 146 Gazette Supplement Lectures and Seminars, Michaelmas term 2015 Witness Seminar (the UN orthopaedics, rheumatology and Islamic Studies at 70) 26 Musculoskeletal Sciences Reuters Institute for the Study of Pathology Journalism Pharmacology Reuters Institute for the Study of Charles Simonyi Lecture 26 Physiology, anatomy and Genetics Journalism/Nuffield Population Health Latin american centre Humanities 26 Psychiatry Foundation for Law, Justice and Society/ centre for Socio-Legal Studies TORCH | The Oxford Research Centre in Social Sciences 34 Learning Institute the Humanities Maison Française Rothermere American Institute anthropology and Museum Ethnography oxford Martin School Classics Archaeology Population ageing English Language and Literature Saïd Business School English/History/History of Art/Theology/ Education Colleges, Halls and Societies 44 Music Geography and the Environment all Souls/Magdalen History Intellectual Property research centre Balliol History/Politics and International Interdisciplinary Area Studies Relations Green templeton International Development (Queen Linguistics, Philology and Phonetics Elizabeth House) Keble Linguistics, Philology and Phonetics/ Law Lady Margaret Hall Medieval and Modern Languages Politics and International relations Magdalen Medieval and Modern Languages Social Policy and Intervention Mansfield Music Socio-legal Studies Nuffield Oriental Studies Sociology Oriel St Anne’s Mathematical, Physical and Department for Continuing St
    [Show full text]